ArticleFrontiers in oncology2025
Predicting survival rates: the power of prognostic nomograms in distal cholangiocarcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study.Journal of gastrointestinal oncology · 2026Article
- FREM1 serves as a novel therapeutic target in breast cancer through basement membrane-based prognostic modeling with integrated bioinformatics and experimental validation.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this research is to establish a prognostic nomogram for patients with distal cholangiocarcinoma (dCCA). Methods: We obtained clinical data from 2401 patients diagnosed with distal cholangiocarcinoma (dCCA) between 2010 and 2020 from the Surveillance, Epidemiology, and End Results database. These patients were randomly assigned to either the training or validation group in a ratio of 6:4. 228 patients were enrolled from 9 hospitals in China as the external validation cohort. Univariate and multifactorial Cox regression analyses were conducted to ascertain prognostic factors and prognostic nomograms were developed utilizing LASSO logistic regression analysis. We used the calibration curve, and area under the curve to validate the nomograms. Decision curve analysis was used to evaluate the model and its clinical applicability. Results: The findings demonstrated that Grade, M stages, Surgery, and Chemotherapy emerged as autonomous prognostic factors for the survival of individuals with dCCA. The developed nomograms exhibited satisfactory accuracy in forecasting 1-year, 3-year, and 5-year survival probabilities. Furthermore, the calibration curves indicated a strong concordance between the anticipated and observed outcomes. The AUC of the nomogram for 1-year, 3-year, 5 year overall survival (OS) predication were 0.809 (95%CI 78.5-83.3), 0.79 (95%CI 75.8-82.2) and 0.761 ((95%CI 72.3-80.0) in the training cohort, 0.79 (95%CI 75.9-82.0), 0.73 (95%CI 68.5-77.5), and 0.732(95%CI 68.0-78.3) in internal test cohort, 0.862 (95%CI 81.7-90.7),0.83 (95%CI 76.4-89.6),and 0.819(95%CI 74.6-89.2) in external test cohort. Conclusion: The nomograms that have been suggested demonstrate strong predictive capability. These tools can assist medical professionals in assessing the prognosis of patients with dCCA and in devising more accurate treatment strategies for them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.